Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Redefining the norms: an interdisciplinary perspective on language testing in multilinguals with acquired and progressive neurogenic disorders.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

MethylCog predicts six-year cognitive ability beyond blood-based ADRD biomarkers.

medRxiv : the preprint server for health sciences·2026
Same author

Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivity.

Alzheimer's research & therapy·2026
Same author

Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.

medRxiv : the preprint server for health sciences·2026
Same author

Development and validation of MethylCog, a blood DNA methylation proxy for cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

James E Galvin1, Michael J Kleiman1, Paul W Estes2

  • 1University of Miami Miller School of Medicine, Boca Raton, FL, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

一个新的计算机认知测试,Cognivue Clarity,结合Cognivue Amyloid风险测量 (CARM),可以有效地选阿尔茨海默病 (AD) 并识别可能具有粉样蛋白阳性的个人.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经学 神经学
  • 认知科学 认知科学
  • 生物标志物发现发现

背景情况:

  • 早期检测粉样蛋白阳性对于及时诊断阿尔茨海默病 (AD) 和由于AD (MCI-AD) 的轻度认知障碍至关重要.
  • 目前检测粉样蛋白阳性的方法通常依赖于昂贵的生物标志物,导致诊断延迟和错过治疗或临床试验机会.

研究的目的:

  • 开发和验证使用认知评估进行MCI-AD和AD的快速,具有成本效益的查范式.
  • 评估Cognivue Clarity和其衍生的Cognivue粉样蛋白风险测量 (CARM) 识别粉样蛋白阳性个体的能力.

主要方法:

  • 来自Bio-Hermes研究的887名参与者接受了Cognivue清晰度测试,粉样蛋白PET扫描和pTau217测量.
  • 使用机器学习方法从Cognivue Clarity数据中推导出4级CARM.
  • 创建了一个2x2选范式,将Cognivue Clarity全球分数和CARM结合起来.

主要成果:

  • 认知清晰度值和CARM水平与粉样蛋白PET SUVR和血pTau217水平显著相关 (p < .001).
  • 粉样蛋白阳性度在CARM值中增加,大多数MCI-AD和AD痴呆病例属于损伤/高风险类别.
  • 真正的对照主要属于不损伤/低风险类别,而非AD病例分布在所有类别中.

结论:

  • 通过10分钟的计算机化测试Cognivue Clarity,可以检测认知障碍,并通过CARM预测粉样蛋白阳性.
  • 使用Cognivue Clarity和CARM的分阶段查方法,可能随后是血pTau217,为早期AD检测提供了一个具有成本效益的策略.
  • 这种方法提高了早期阿尔茨海默病治疗和临床试验招生个体的识别,绕过了昂贵的PET扫描的需要.